C hronic kidney disease (CKD) is a broad term used to describe any abnormality of kidney structure or function. It is often asymptomatic in the early stages and co-exists with other chronic illnesses, such as diabetes and hypertension. It is associated with an increased risk of cardiovascular disease, end-stage renal failure, anaemia and metabolic bone disease. Early detection of CKD and managing risk factors may provide an opportunity to prevent progression of associated risks. This article will discuss the diagnosis, classification, management and complications of CKD, and when to refer to secondary care.
THE GP curriculum and chronic kidney disease
Clinical module 3.12: Cardiovascular health states that a GP should be able to:
. Demonstrate an understanding of the importance of risk factors, including chronic kidney disease, in the diagnosis and management of cardiovascular problems
Clinical module 3.17: Care of people with metabolic problems states that a GP should be able to:
. Recognise that patients with metabolic problems are frequently asymptomatic or have non-specific symptoms and that diagnosis is often made by screening or recognising symptom complexes and arranging appropriate investigations
. Know the indications for referral to. . .(a) nephrologist for investigation of . . . diabetic renal complications
Chronic kidney disease
Chronic kidney disease (CKD) is a complex condition encompassing a broad heterogeneity of disease processes that often co-exist and overlap with other chronic illnesses, especially vasculopathies. The most common causes of CKD are diabetes and hypertension (Levey & Coresh, 2012) . The burden of disease is significant, with current primary care data suggesting approximately 8.5% of the UK population suffer with moderate to severe CKD (stages 3 to 5) (National Institute for Health and Care Excellence (NICE), 2014). Thus, at least 500 patients will have CKD stages 3 to 5 in an average GP list size of 10 000.
CKD is a risk factor for progression to end-stage renal failure (ESRF) (Gansevoort et al., 2011) , although only a small number of patients (2%) do so, requiring renal replacement therapy (NICE, 2014) . By far, the most significant implication of CKD is the associated increased risk of cardiovascular disease (CVD) and all-cause mortality (Matsushita et al., 2010) . In fact, patients with CKD are approximately 20 times more likely to die of CVD than progress to ESRF, and the allcause mortality is 30-60 times higher than in the general population (NHS Employers and GP Committee of the BMA, 2011). Therefore, the early identification of patients with CKD provides real scope for reducing the risk of CVD and mortality in the general population.
Controversy
It is clear that some healthy people may meet the defined criteria for CKD, which can be detrimental psychologically to the patient and economically to the health service (Moynihan, Glassock, & Doust, 2013) . However, it is increasingly apparent that CKD can affect investigations, pharmacokinetics of renally excreted drugs and treatment outcomes. For example, measuring troponin for cardiac strain may be falsely raised in patients with CKD, due to reduced renal clearance (Stacy et al., 2014) . Compounding this further is the fact that patients with CKD are often excluded from clinical trials, so the risks associated with the diagnosis may be underestimated (O'Hare et al., 2009) . Therefore, despite the potential risk of harm from over diagnosis, early detection and diagnosis of CKD is necessary, important and justified.
Screening
The difficulty with the diagnosis of CKD lies in the asymptomatic (or non-specific symptomatic) nature of early disease. Many patients are picked up incidentally on routine check-ups or while investigating another presentation. Population screening for CKD is not economically viable, and there is little evidence to suggest this improves the outcomes of renal failure and CVD (NICE, 2016) .
However, there are significant risk factors for CKD, and for some of these screening is deemed cost-effective (Fig. 1 ). This diagram also illustrates how many of these risks can also go on to cause and progress CKD.
Although the prevalence of CKD increases with age, ageing is not currently highlighted as a risk factor for CKD (NICE, 2016) . This is because longitudinal studies show that despite an average decrease in renal function with age, development of CKD is not inevitable for all patients (Lindeman, Tobin, & Shock. 1985) . Instead, the increased prevalence of CKD in elderly patients is thought to be linked to an increase in other factors, such as proteinuria, hypertension and diabetes, all of which can lead to more rapid progression of CKD (Webster, Bagler, Morton, & Mason, 2017) .
Measuring kidney function
The definition of CKD has evolved over time, with the currently accepted understanding of it having been developed by The Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (KDIGO CKD Working Group, 2012) , and is shown in Box 1.
CKD is therefore investigated using a blood test for estimated glomerular filtration rate (eGFR) and urine albumin: creatinine ratio (uACR), simple investigations that can be organised in primary care and used to monitor CKD and CKD progression.
Estimated glomerular filtration rate
The eGFR is obtained by combining the serum creatinine level with other parameters such as age and gender using the Chronic Kidney Disease Epidemiology Collaboration (CKD -EPI) equation (NICE, 2016 In CKD, proteinuria is an independent risk factor for progression of renal disease and early reductions are shown to slow this progression (Matsushita et al., 2010) . A urine dipstick is not sensitive enough to pick-up early proteinuria. Albumin, the most common protein to be excreted in the urine, is used for its sensitivity at low grade proteinuria, and measured using the uACR. The gold standard for testing is a 24-hour urine collection, but this is not practical or feasible in primary care. Instead, a spot urine sample, done early in the morning to exclude orthostatic proteinuria, is an effective alternative.
Diagnosis and staging
If CKD is suspected, initially one should investigate for and exclude reversible causes, such as nephrotoxic drugs or obstruction. Medical emergencies, such as fluid overload, hyperkalaemia or severe uraemia, should be referred straight to hospital. If haematuria is present and persistent, and a urinary tract infection has been excluded, referral to urology under the 2-week rule is necessary to exclude malignancy. An ultrasound scan of the kidneys may also be considered, for example, if the patient has a family history of polycystic kidney disease.
CKD is diagnosed, as described above, by testing for the eGFR and uACR and using them in combination to obtain the five stages of CKD (Table 1) . Both falling eGFR and rising uACR are good independent risk factors of all-cause and cardiovascular mortality (Matsushita et al., 2010) , as well as ESRF, AKI, and progression of CKD (Gansevoort et al., 2011) .
Stages 1 to 3 are usually managed in primary care, but stages 4 and 5, may warrant renal review, by virtue of the complications associated with nearing ESRF. Patients in the same CKD stage may have different risks for CKD, ESRF, or mortality, depending on their co-morbidities, but the overall risks for these outcomes increase with severity of CKD (Shlipak et al., 2013) .
If the eGFR alone suggests stage 3 CKD or above (in the absence of proteinuria), it is best to repeat this within 2 weeks, ensuring the sample is taken optimally (an early morning urine sample, blood taken at the hospital and no meat 12 hours before testing 
Acute kidney injury
AKI is a medical emergency and needs urgent referral to hospital. The criteria for AKI are shown in Box 2 (NICE, 2013). AKI is a well-known risk factor for CKD and its progression, and conversely, CKD is an independent risk factor for AKI (Bedford, Farmer, Levin, Ali, & Stevens, 2012) . Patients with CKD who have AKI are particularly vulnerable to the risks of renal impairment, due to reduced renal reserve, and should be monitored closely to prevent further progression of CKD.
Management
The diagnosis of CKD and the implications of diagnosis should be discussed early on with the patient. The general principles of management focus on managing the risk factors for CKD and its 
Hypertension and proteinuria
As well as being a risk factor for and cause of CKD, uncontrolled hypertension is associated with progression of disease and can also itself, be a complication of CKD (Webster et al., 2017) . Therefore, If there is evidence of significant proteinuria (uACR greater than 70 mg/mmol), a meta-analysis has shown that more intensive blood pressure lowering to less than 130/80 mmhg can reduce the progression to ESRF, but not cardiovascular disease (Lv et al., 2013) . Again, the most benefit is derived with the use of ACE inhibitors and ARBs, which should also be used in patients to treat significant proteinuria, even in the absence of hypertension (NICE, 2016) .
Statins
All patients with CKD should be offered 20 mg atorvastatin as primary or secondary prophylaxis of CVD (NICE, 2016 
Anticoagulation
This is no longer advised in primary prevention of CVD in patients with CKD, but is used with caution in secondary prevention. This is due to a paradoxical rise in both the thrombotic and bleeding tendencies in patients with CKD.
CKD and diabetes
Diabetes is the most common cause of renal failure in the UK, with patients usually developing progressive kidney disease over many years (Gilg, Caskey, & Fogarty, 2016) . The underlying pathophysiology of diabetic nephropathy is typically one of glomerulosclerosis, which clinically manifests as hypertension, albuminuria and worsening eGFR, sometimes with nephrotic syndrome (Levey & Coresh, 2012 ).
The risk factors for developing diabetic nephropathy include poor glycaemic control, uncontrolled hypertension, smoking and deranged lipid profiles (Iqbal & Shah, 2011) . Addressing these factors early in the management of diabetes is therefore important in preventing the development of CKD. It is well-recognised that tight glycaemic control slows the development of diabetic nephropathy. However, there is insufficient evidence to show this tight control also slows CKD progression (Levey & Coresh, 2012) . Therefore, diabetic targets, once diabetic nephropathy is established, should continue to be individualised to the patient, depending on symptoms and co-morbidities.
If the diabetic patient has hypertension, the BP should be kept 
Complications
As CKD progresses and kidney function worsens, the ability to regulate acid/base, electrolyte and fluid balance becomes impaired.
Symptoms start to develop due to the accumulation of uraemic retention solutes, and in particular uraemic toxins, that have adverse physiological effects (Webster et al., 2017) . These substances are 
Anaemia
Patients with CKD may develop a normochromic, normocytic anaemia, due to a combination of reduced erythropoietin production, increased red blood cell fragility and uraemia-induced inhibition of erythropoiesis (Webster et al., 2017) . This is more common in stages 3 b to 5 of CKD and should be checked for, if not previously done. However, it is not routinely recommended to screen for InnovAiT anaemia in CKD stages 1 to 3 a unless the patient is symptomatic (NICE, 2014) . Anaemia in any patient with an eGFR less than 60 mL/ min/1.73 m 2 should be investigated to see if this is related to CKD (NICE, 2015) .
The anaemia of chronic disease related to CKD is associated with increased CVD and mortality, so it is important to address (Webster et al., 2017) . This is usually on the advice of the renal physician and consists of oral iron, recombinant erythropoietin or its synthetic derivatives. The aim should not be to raise the haemoglobin to normal levels, as this confers an increased risk of thrombosis, but rather to an aspirational level between 100 and 120 g/L, though this will vary per patient and their symptoms (NICE, 2015) .
Bone disease
The kidneys are responsible for the second hydroxylation of vitamin D to form calcitriol, the hormonally active metabolite central to bone metabolism. It works to increase intestinal absorption of dietary calcium, renal tubular reabsorption of calcium and secretion of phosphate, and osteoclastic activity in the bones. In CKD, there is less calcitriol formation and therefore a fall in serum calcium and rise in phosphate. The parathyroid hormone (PTH), which normally regulates this process by negative feedback and activated by low calcium is now secondarily increased. Long-standing impairment leads to tertiary hyperparathyroidism and raised calcium.
Bone profile monitoring (calcium, phosphate, vitamin D, and PTH levels) is therefore important in CKD and adding in alkaline phosphatase can improve the predictive power of monitoring (Steddon & Sharples, 2015) . However, patients are often asymptomatic in early disease (CKD stages 1 to 3) and the clinical significance of deranged results in these groups is unclear; therefore, routine testing above an eGFR of 30 mL/min/1.73 m 2 is not currently recommended (NICE, 2014) . Screening for a deranged bone profile should be undertaken in CKD stages 4 and 5 and the frequency of monitoring depends on symptoms, severity and rate of CKD progression.
Therapeutic intervention, which is usually coordinated by nephrology, should be targeted to trends in parameters, rather than single readings.
Vitamin D replacement should be given to patients with documented vitamin D deficiency, and not simply to prevent bone disease (NICE, 2014) . This has no effect on the risk of progression to ESRF. 
Cancer
There is an increased risk of cancer in patients with CKD, which is considerably higher in patients with ESRF and on dialysis (Webster et al., 2017) . Some studies have shown this risk to be related to falling eGFR and rising proteinuria. However, the cause for this is likely to be multifactorial, and given the unpredictable nature of investigations and toxicity of treatments, screening for cancer beyond the national programmes is not currently recommended.
End-stage renal failure
The pathological end stage in CKD is typically renal fibrosis, via a combination of glomerulosclerosis, tubular atrophy and interstitial disease, following repetitive damage and incomplete healing (Webster et al., 2017) . Patients with ESRF or who are on dialysis have a higher risk of CVD, mortality and complications of renal failure, including peripheral neuropathies, malnutrition and cognitive impairment.
Their care is almost always co-ordinated by the renal physicians, so the role of the GP here is limited.
However, the deterioration in renal function is difficult to predict, and it is possible that some patients with CKD stage 4 remain stable and are monitored by primary care for a period. In this case, 
Indications for referral
A summary of the key issues in CKD management that vary by severity of CKD is shown in Table 2 . The main reasons for referral to nephrology include severity of CKD (worsening eGFR/ rising proteinuria/ complications), rapid decline in renal function or known structural abnormality (Box 3). A renal biopsy is sometimes performed by the renal team if the aetiology is unclear to guide therapeutic intervention.
KEY POINTS
. CKD is common, frequently asymptomatic, insidious and often associated with other co-morbidities
. CKD increases the risk of CVD significantly, more so than renal failure
. Being alert to the possibility of CKD and screening those patients at high risk provides an opportunity to reduce risk of CVD, mortality and CKD progression
. Monitoring of CKD and screening for complications is individualised to the patient, their risk factors and co-morbidities
. Management consists of addressing the risk factors for deterioration of renal function and CVD, notably hypertension and diabetes . Rapid progression and complications of CKD are a sign of poor prognosis and should be referred to the renal physicians appropriately
